6976-17-6 Usage
Description
4-(METHYLAMINO)BUTYRIC ACID HYDROCHLORIDE, also known as the salt form of N-Methyl-4-aminobutyric Acid (M285745), is a GABA derivative and a hydrolysis product of the industrial solvent, N-methyl-2-pyrrolidinone. It is biologically a product of nicotine catabolism in bacteria and inhibits L-Carnitine from undergoing β-oxidation in mammals. It is characterized by its white crystalline powder appearance.
Uses
Used in Pharmaceutical Industry:
4-(METHYLAMINO)BUTYRIC ACID HYDROCHLORIDE is used as an intermediate compound for the synthesis of various pharmaceuticals, due to its role as a GABA derivative and its involvement in biological processes.
Used in Cosmetics Industry:
4-(METHYLAMINO)BUTYRIC ACID HYDROCHLORIDE is used as an active ingredient in skin products for the prevention of wrinkles, as it helps in maintaining the skin's elasticity and firmness.
Used in Chemical Research:
4-(METHYLAMINO)BUTYRIC ACID HYDROCHLORIDE is used as a research compound for studying the effects of GABA derivatives on the central nervous system and their potential applications in the treatment of neurological disorders.
Used in Industrial Solvent Production:
4-(METHYLAMINO)BUTYRIC ACID HYDROCHLORIDE is used as a starting material in the production of N-methyl-2-pyrrolidinone, an industrial solvent with various applications in the chemical, pharmaceutical, and agricultural industries.
Check Digit Verification of cas no
The CAS Registry Mumber 6976-17-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,9,7 and 6 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 6976-17:
(6*6)+(5*9)+(4*7)+(3*6)+(2*1)+(1*7)=136
136 % 10 = 6
So 6976-17-6 is a valid CAS Registry Number.
InChI:InChI=1/C5H11NO2.ClH/c1-6-4-2-3-5(7)8;/h6H,2-4H2,1H3,(H,7,8);1H
6976-17-6Relevant articles and documents
ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
-
Paragraph 000221, (2021/02/05)
Disclosed here is an adenosine derivative prodrug that can have reverse transcriptase inhibitor activity in vivo. This disclosure is also directed to a pharmaceutical composition comprising the adenosine derivative that can be used for the treatment of HIV infection or RNA virus infection.
Synthesis and evaluation of xanomeline analogs-Probing the wash-resistant phenomenon at the M1 muscarinic acetylcholine receptor
Kane, Brian E.,Grant, Marianne K.O.,El-Fakahany, Esam E.,Ferguson, David M.
, p. 1376 - 1392 (2008/09/18)
A series of xanomeline analogs were synthesized and evaluated for binding at the M1 muscarinic acetylcholine receptor (M1 receptor). Specifically, compounds that substitute the O-hexyl chain of xanomeline with polar, ionizable, or conformationally restricted moieties were assessed for their ability to bind to the M1 receptor in a wash-resistant manner (persistent binding). From our screen, several novel ligands that persistently bind to the M1 receptor with greater affinity than xanomeline were discovered. Results indicate that persistent binding may arise not only from hydrophobic interactions but also from ionic interactions with a secondary M1 receptor binding site. Herein, a qualitative model that accounts for both binding scenarios is proposed and applied to understand the structural basis to wash-resistant binding and long-acting effects of xanomeline-based compounds.
